

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

EP 0 892 643 B1

## EUROPEAN PATENT SPECIFICATION

(12)

(45) Date of publication and mention  
of the grant of the patent:  
19.06.2002 Bulletin 2002/28

(21) Application number: 97916037.1

(22) Date of filing: 20.03.1997

(51) Int Cl.7: A61K 39/395, A61K 38/17  
// (A61K39/395, 38:17)

(86) International application number:  
PCT/US97/04248

(87) International publication number:  
WO 97/34633 (25.09.1997 Gazette 1997/41)

(54) METHODS FOR INHIBITING AN IMMUNE RESPONSE BY BLOCKING THE GP39/CD40 AND  
CTLA4/CD28/B7 PATHWAYS AND COMPOSITIONS FOR USE THEREWITH

VERFAHREN ZUR INHIBIERUNG DER IMMUNREAKTION DURCH BLOCKIERUNG DER  
GP39/CD40 UND CTLA4/CD28/B7 ROUTEN UND ZUSAMMENSETZUNG ZU DEREN  
VERWENDUNG

PROCEDES D'INHIBITION D'UNE REPOSE IMMUNE PAR BLOCAGE DES VOIES DE  
GP39/CD40 ET CTLA4/CD28/B7 ET COMPOSITIONS UTILISEES AVEC CEUX-CI

(84) Designated Contracting States:  
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE

(30) Priority: 20.03.1996 US 13751 P

(43) Date of publication of application:  
27.01.1999 Bulletin 1999/04

(80) Divisional application:  
01119521.1 / 1 186 300

(73) Proprietors:  
• Bristol-Myers Squibb Company  
Seattle, WA 98121 (US)  
• Emory University  
Atlanta, Georgia 30322 (US)

(72) Inventors:  
• LARSEN, Christian, P.  
Atlanta, GA 30345 (US)  
• ARUFFO, Alejandro, A.  
Edmonds, WA 98020 (US)  
• HOLLENBAUGH, Diane, L.  
Seattle, WA 98117 (US)  
• LINSLEY, Peter, S.  
Seattle, WA 98119 (US)  
• LEDBETTER, Jeffrey, A.  
Seattle, WA 98117 (US)  
• PEARSON, Thomas, C.  
Atlanta, GA 30307 (US)

(74) Representative: Kinzebach, Werner, Dr. et al  
Patentanwältin  
Reitschötter, Kinzebach und Partner  
Postfach 86 06 49  
81633 München (DE)

(56) References cited:  
EP-A- 0 555 880 WO-A-92/00092  
WO-A-94/01547 WO-A-96/39514  
AU-A- 9 476 445 US-A- 5 662 224  
US-A- 5 677 165 US-A- 5 683 693  
US-A- 5 698 679

- JOURNAL OF CELLULAR BIOCHEMISTRY, SUPPLEMENT, vol. 0, no. 21 part A, 1995, NEW YORK, NY, USA, page 141 XP002037030 N. GRIGGS ET AL.: "Contribution of CD28/CTLA4/B7 and gp39/CD40 costimulation pathways in clonal expansion and functional acquisition of self-reactive T cells."
- SURGICAL FORUM, vol. 47, no. 0, 1996, PHILADELPHIA, PA, USA, pages 427-429, XP002037031 E. ELWOOD ET AL.: "Long-term murine skin allograft survival with peroperative CTLA4-Ig and anti-gp39: The role of CD4+ T cells."
- EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 25, no. 2, February 1995, WEINHEIM, GERMANY, pages 596-603, XP002037032 M. ROY ET AL.: "Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses."

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 892 643 B1